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Organismal aging is a multifactorial process characterized by the onset of
degenerative conditions and cancer. One of the key drivers of aging is
cellular senescence, a state of irreversible growth arrest induced by many
pro-tumorigenic stresses. Senescent cells accumulate late in life and at sites
of age-related pathologies, where they contribute to disease onset and
progression through complex cell and non-cell autonomous effects. Here,
we summarize the mechanisms by which cellular senescence can promote
aging, and we offer an extensive description of current potential
pharmacological interventions for senescent cells, highlighting
limitations and suggesting alternatives.on Aging, California US.
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Cellular senescence is a stress response characterized by the induction of a permanent cell cycle
arrest. Senescence represents an important barrier to tumorigenesis by limiting the growth of
potentially oncogenic cells, reviewed in [1]. To date, there is no single universal marker that can
differentiate senescent cells from quiescent, terminally differentiated and other nonproliferating
cells. Instead, multiple markers are combined to identify senescent cells including: (i) upregula-
tion of p16INK4a, a protein that prevents cell cycle progression from the G1 to S phases by
inhibiting cyclin-dependent kinase (CDK)4 and CDK6 [2]; (ii) activation of the lysosomal enzyme
senescence-associated b-galactosidase (SA-b-gal) [3]; (iii) formation of specialized domains of
facultative heterochromatin that contribute to silencing of proliferation-promoting genes in
senescent cells, known as senescence-associated heterochromatin foci (SAHF) [4]; and (iv)
persistent signaling of the DNA damage response (DDR), as shown by the presence of p53-
binding protein 1 (53BP1) and gH2AX foci [5]. Most studies rely on thesemarkers, although other
predictive markers of senescence such as a flattened morphology, absence of the proliferation
marker Ki67, enlarged nuclear size, loss of nuclear high mobility group box 1 (HMGB1) and
decreased expression of lamin B1 are also often described [6].
Senescence-associated growth arrest (SAGA) is accompanied by an overactive secretory phe-
notype known as the senescence-associated secretory phenotype (SASP) [7]. The SASP consists of
numerous cytokines, growth factors, proteases and extracellular matrix components that,Corresponding author: Demaria, M. (m.demaria@umcg.nl)
786 www.drugdiscoverytoday.com
1359-6446/ 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.drudis.2017.01.004

















Wdepending on the physiological context, can be either beneficial or
deleterious. During early stages, SASP components promote the
migration and infiltration of effector immune cells through the
secretion of cytokines and facilitate tissue repair and remodeling
by release of growth factors and proteases [8]; however, in later
stages, persistent senescent cells negatively impact the surround-
ing microenvironment by impairing tissue homeostasis through
complex cell and non-cell autonomous effects, reviewed in [9].
In a cell-autonomous manner, selected SASP components such
as interleukin (IL)-6 and IL-8 can reinforce SAGA through auto-
crine pathways [10,11]. However, the same secreted components
can act in paracrine signaling to neighboring cells, propagating the
senescent phenotype and thus potentially hampering the regen-
erative capacity of surrounding tissue [12]. Similarly, in a non-cell-
autonomous manner, SASP cytokines promote infiltration of im-
mune cells, yet persistent signaling can result in disruptive chronic
inflammation [13], a hallmark of aging and major contributor to
age-related dysfunctions [13–18]. Indeed, senescent cells accumu-
late late in life and at sites of age-related pathologies [19–21], and
genetic interventions enabling the effective clearance of senescent
cells in genetically engineered animal models is sufficient to delay
a number of age-related phenotypes [22–25].
Accordingly, a prolonged healthspan is obtained by pharmaco-
logical interventions using a novel class of drugs termed senoly-
tics, used to selectively ablate senescent cells [26]. Senolytic
interventions not only demonstrated the feasibility of extending
healthspan but also evidenced the alleviation of a wide range of
pre-existent age-related symptoms including: improved cardiovas-
cular function, reduced osteoporosis and frailty [26]; enhanced
adipogenesis, reduced lipotoxicity and increased insulin sensitivi-
ty [27]; improved established vascular phenotypes associated with
aging and chronic hypercholesterolemia [28]; as well as radiopro-
tection and rejuvenation of aged-tissue stem cells [29]. In this
review, we will summarize the mechanisms by which cellular
senescence can promote aging, followed by an extensive descrip-
tion of current potential pharmacological interventions for sup-
pressing the SASP or selectively eliminating senescent cells (Fig. 1).
Interfering with the paracrine signaling of senescent
cells
Pathways involved in SASP regulation
The senescence response can be promoted by a variety of stressors,
such as activation of oncogenes, telomere shortening, genotoxic
and oxidative stress. Various signaling pathways are activated in a
stress-type-dependent fashion, yet they appear ultimately to con-
verge with nuclear factor (NF)-kB signaling [30]. Similarly, specific
SASP components vary largely on a cell-type-dependent manner,
but key components are NF-kB-dependent proinflammatory pro-
teins. Indeed, the canonical SASP cytokines IL-6 and IL-8 appear to
be the most conserved and robustly expressed cytokines of the
SASP [16,17]. Cytokines have multiple autocrine and paracrine
effects that are considered pleiotropic. They positively regulate a
variety of cellular functions, including immune responses, growth
arrest and/or differentiation [31]. By contrast, in human malig-
nancies they can stimulate cell migration, growth, invasion, an-
giogenesis and eventually promote metastasis, reviewed in [32].
Such observations partly explain the paradoxical roles for cellular
senescence as a tumor suppressor and a tumor promoter.The robust expression of IL-6 and IL-8 not only contributes to
the induction of the SASP but also helps its maintenance, by
activating a self-amplifying secretory program. Indeed, an auto-
crine positive feedback loop is initiated by the activation of
transcription factors NF-kB and the CCAAT/enhancer binding
protein beta (C/EBPb), which transactivate numerous genes, in-
cluding the coordinated expression of IL-6 and IL-8 as well as their
respective receptors IL-6R/GP80 and IL-8RB/CXCR2 [10,11,33].
Several pathways have been identified as regulators of the SASP
by influencing NF-kB at various levels. These include mammalian
target of rapamycin (mTOR) [34,35], mitogen-activated protein
kinase (MAPK) signaling [36], the phosphoinositide 3 kinase (PI3K)
pathway [37] and GATA4/p62-mediated autophagy [38]. The
mTOR complex is a keymodulator of aging and age-related disease
in various species [39]. The exact mechanisms by which mTOR
regulates aging are unclear, but novel studies suggest a role in
cellular senescence and the SASP. Indeed, the mTOR complex was
shown to specifically promote the translation of the proinflam-
matory cytokine IL-1a [34], which is thought to be an early
regulator of the SASP that subsequently engages the IL-6/IL-8
pathways. Indeed, coupling of IL-1a to its receptor (IL-1R) via
juxtacrine signaling enables a positive feedback loop that stimu-
lates their own expression through activation of IL-1 receptor-
associated kinase (IRAK)1, an upstream regulator of NF-kB activity,
and the transcription factor C/EBPb [40]. Moreover, mTOR is also
thought to interact with MAPK by increasing translation of the
MK2 kinase (also known as MAPKAPK2), which acts by preventing
the degradation of numerous SASP factor transcripts by ZFP36L1
[35]. In turn, MAPKAPK2 is itself a downstream target of
p38MAPK, demonstrating that SASP can depend on the activation
of additional signaling pathways [41].
Different components of insulin growth factor (IGF) signaling,
such as the IGF-binding proteins IGFBP3 [42], IGFBP4 and IGFBP7
[36,43] are part of the SASP and act through autocrine/paracrine
pathways to inhibit IGF signaling. Tissue plasminogen (t-PA) and
PAI-1 are also observed in the secretome of senescent cells follow-
ing different genotoxic stresses [37,44]. The SASP factor transform-
ing growth factor beta (TGF-b) can reinforce senescence via
paracrine and autocrine mechanisms. In a paracrine fashion, it
can induce bystander senescence in neighboring cells by generat-
ing reactive oxygen species (ROS) and DNA damage, triggering
chronic DDR signaling [45]. In an autocrine fashion, TGF-b sig-
naling ensures a stable cell cycle arrest through the establishment
of a positive feedback loop leading to p15INK4b induction, even
after loss of p16INK4A [46].
NF-kB-based strategies to interfere with the SASP
Given the deleterious effects of some SASP components, therapeu-
tic strategies for targeting the SASP without disturbing the growth
arrest are currently being investigated (Fig. 2). Senescent cells are
thought to contribute to tissue dysfunction largely through chron-
ic inflammation. Pharmaceutical strategies using known anti-in-
flammatory drugs have therefore been approached as effective
SASP modulators.
Glucocorticoids are a group of steroid hormones secreted from
the adrenal cortex when the body senses stress [47], and include
cortisol and corticosterone. Both hormones have strong anti-in-
flammatory activities and are consequently used in the treatmentwww.drugdiscoverytoday.com 787
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FIGURE 1
Therapeutic interventions against aging relating to cellular senescence. Various drugs interfere with the secretory phenotype of senescent cells, suggesting their
clinical use for the suppression of deleterious effects associated to the senescence-associated secretory phenotype (SASP). Alternative drugs, senolytics, block pro-
survival pathways active in senescent cells leading to apoptosis. Another potential approach to target senescent cells is by enhancing natural clearance by means
of immunotherapy through the use of immunemodulators or by increasing the number of immune effector cells. Finally, therapeutic interventions for the bypass















Wof various conditions, including asthma, allergies, autoimmune
diseases and certain cancers [48]. Importantly, one of their mech-
anisms of action is through repression of proinflammatory cyto-
kines [49]. Their effect on the SASP was therefore studied,
demonstrating decreased secretion of selected SASP components
including IL-6 [50]. The suppressive effect on the SASP was found
to be largely caused by the ability of glucocorticoids to down-
regulate NF-kB transcriptional activity, suggesting the FDA-ap-
proved drugs might partly exert their beneficial effects by
suppressing SASP-induced inflammation. Unfortunately, side-
effects and drug resistance are associated with long-term thera-
peutic doses of glucocorticoids, compromising their clinical appli-
cations in age-related degeneration, and possibly requiring dosage
re-evaluation if intended for aging interventions.
Other commercially approved drugs have been similarly evalu-
ated for their use as SASP regulators. Metformin (1,1-dimethylbi-
guanide) is a commercially available antidiabetic drug with
additional effects in lowering risks of microvascular and myocar-
dial infarction [51], cancer occurrence and general mortality,
reviewed in [52]. One of the metformin modes of action involves
preventing the translocation of NF-kB to the nucleus, effectively
disabling activation of the NF-kB pathway [53]. An inhibitory
effect of metformin on the SASP was therefore demonstrated by
Moiseeva et al.who showed reduction in growth of prostate cancer
cells otherwise fueled by SASP cytokines in the absence of metfor-
min [54]. Similarly, prolonged tumor remission was observed in
mouse xenograft cancer models upon treatment with metformin
in combination with chemotherapy agents [55,56]. Lastly, as a
general antiaging agent, Martin-Montalvo et al. demonstrated that
metformin reduces oxidative stress and inflammation, extending
lifespan and healthspan in mice [57]. The evidence provided by788 www.drugdiscoverytoday.comthese studies has paved the way for ongoing clinical studies to
examine the effects of metformin on human aging and longevity
(NCT02432287).
Comparably, natural compounds, like the phenol resveratrol
[58] or the flavonoids apigenin, wogonin and kaempferol, have
also been shown to dampen the SASP, probably through their
interaction with IkB kinases [59]. To identify novel downstream
effector kinases in cellular senescence, Ferrand et al. screened a
library of activated kinases, successfully identifying several kinases
where constitutive expression induced known markers of senes-
cence. Remarkably, the researchers also demonstrated that the
kinases with the strongest pro-senescence effects induced the
expression of SASP genes through activation of NF-kB [60]. How-
ever, NF-kB covers multiple functions, and its dysregulationmight
lead to severe consequences [61]. Identifying the specific context
in which each kinase is activated is a key task for the design of less
toxic interventions to limit the SASP.
A potential pharmacological alternative to dampen the SASP
resides in modulating the upstream regulators of NF-kB activity.
Indeed, using anti-IL-1a neutralizing antibodies or recombinant
IL-1R antagonists, Orjalo and colleagues effectively disrupted the
autocrine IL-1a–NF-kB positive feedback loop, markedly reducing
the secretion of the canonical SASP cytokines IL-6 and IL-8 [40]. In
the same way, because mTOR regulates the expression of mem-
brane-bound IL-1a in senescent cells, selective mTOR inhibitors
like rapamycin can also interfere with the IL-1a–NF-kB loop con-
trolling much of the SASP [34]. Because rapamycin prevents the
permanent loss of proliferative potential in arrested cells, without
inducing proliferation [62], it can act by allowing cells to stop cell
cycle progression in the face of a stressor, yet effectively suppres-
sing SASP components that would otherwise hold arrested cells in
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FIGURE 2
Senescence-associated secretory phenotype (SASP). Various drugs have been shown to lower production or secretion of several SASP factors. In particular,
compounds that interfere with the nuclear factor (NF)-kB, Janus kinase (JAK)/signal transducer and activator of transcription (STAT), mitogen-activated protein

















Wan irreversible SAGA, or potentially propagate the senescence
phenotype. Rapamycin and several analogs (known as rapalogs)
selectively inhibit the mTOR complex 1 (mTORC1). By contrast,
‘non-rapalog’ dual mTORC1/C2 inhibitors act in a broader spec-
trum, simultaneously targetingmTORC1 andmTORC2 complexes
[63]. Alternatives to rapamycin with superior pharmacological
properties have therefore been suggested as antiaging therapeutics
[64,65].
The interaction of mTOR with the MAPK pathway, and DDR-
independent SASP regulation through MAPK signaling, has
prompted members of the phosphorylation cascade to be consid-
ered as alternative pharmaceutical targets. The p38MAPK inhibitor
SB203580 and the more-specific next-generation inhibitors UR-
13756 and BIRB 796 all markedly suppressed SASP expression in
senescent cells [41,66]. Comparably, the p38 downstream MK2
kinase (MAPKAPK) inhibitors PF-3644022 and MK2.III were also
effective in dampening the SASP. Among these, BIRB 796 has
already reached Phase III clinical trials, suggesting its possible
use to suppress the SASP in vivo [66].NF-kB-independent strategies to interfere with the SASP
The Janus kinase/signal transducer and activator of transcription
(JAK/STAT) pathway is a major regulator of cytokine production.
In senescent cells, JAK/STAT signaling is thought to sustain the IL-
6 autocrine positive feedback loop that helps reinforce senescence;
binding of IL-6 to its receptor is thought to signal via JAK/STAT to
activate the transcription factor C/EBPb [67], which then drives
expression of IL-6 and IL-8 [10]. Many SASP factors such as IL-6,
MCP-1, vascular endothelial growth factor (VEGF) and type I/II
interferons are also activators of the pathway [68]. Thus, repro-
graming of the SASP using JAK inhibitors has been investigated in
cancer and age-related dysfunctions [69]. In oncology, enhanced
chemotherapy efficacy was demonstrated using a JAK2 inhibitor
[70], whereas positive effects in various age-related symptoms
including reduced systemic inflammation, enhanced physical
capacity, metabolic function, preserved fat tissue homeostasis,
improved muscle stem cell function, muscle regeneration and
hair growth promotion have been described for inhibitors like
ruxolitinib (JAK1/2) [27] and tofacitinib (JAK1/3), reviewed in [69].www.drugdiscoverytoday.com 789















WAn additional approach for NF-kB-independent SASP disruption
appears to be through inhibition of protein prenylation, a post-
translational modification required by key SASP components [71].
Statins are a group of cholesterol-lowering drugs that act by
inhibiting the first and rate-limiting enzyme of the mevalonate
pathway (HMG-CoA, HMGCR), thereby reducing cholesterol for-
mation, as well as formation of isoprenoid intermediates essential
for protein prenylation. The inhibitory effects of statins in protein
prenylation could thus be exploited in dampening the SASP, and
perhaps partly explaining the anti-inflammatory effects observed
in selected statins [72,73]. Simvastatin treatment reduces the
expression of proinflammatory cytokines such as IL-6, IL-8 and
monocyte chemoattractant protein (MCP)-1 in vitro and in vivo
[74,75] and can effectively suppress the effects of the SASP in
fueling cancer proliferation [76]. Interestingly, known prenylated
proteins include several protein kinases, signal transduction
switches of the Ras superfamily and the nuclear lamina protein
lamin A, which is implicated in the pathogenesis of Hutchinson–
Gilford progeria syndrome. The use of prenyltransferase inhibitors
is therefore actively investigated in progeria, cancer and aging [71].
Finally, other alternatives to counteract deleterious effects of
the SASP include the use of neutralizing agents to block or seques-
ter selected SASP components, thus hampering their biological
action. For instance, IL-6 and IL-8 have important autocrine roles
in senescence maintenance, as well as in the induction of tumor-
promoting phenotypes; other SASP factors such as VEGF support
increased angiogenesis [77], or act as immunosuppressants (TGF-
b) [78]. These effects make selected SASP components interesting
therapeutic targets. Of note, monoclonal antibodies directed
against IL-6 [79], IL-8 [80], VEGF [81] or TGF-b [82] are already
in development or approved for the market for the treatment of
various malignancies. However, their direct effect on the accumu-
lation of senescent cells in vivo remains to be tested. Similarly,
additional SASP factors, such as secreted proteases and matrix-
remodeling enzymes, also participate in tissue structure disruption
and are key regulators in cancer and inflammation [83]; the
administration of synthetic inhibitors to hamper these effects
would therefore represent an interesting alternative.
Natural clearance of senescent cells
To prevent deleterious effects stimulated by their persistence,
increasing evidence suggests the immunogenic phenotype of se-
nescent cells also consists of the upregulation of surface ligands
not normally expressed on healthy tissue. Indeed, natural killer
(NK) cells and subsets of T cells trigger cytolytic responses on
senescent cells. This phenomenon, termed senescence surveil-
lance [84], has been demonstrated in the liver and appears to be
mediated by activation of the NKG2D receptor [85–88].
The NKG2D receptor recognizes ligands on the surface of
stressed cells leading to direct cytotoxicity [89–91]. NKG2D ligands
are poorly expressed in normal cells, but are frequently upregu-
lated in stressed, precancerous and tumor cells, as well as some
infected cells [92]. Themechanisms leading to ligand upregulation
are still unknown, but experimental evidence suggests the involve-
ment of the DDR pathway [93]. Furthermore, similar to senescent
cells propagating the senescence phenotype via SASP cytokines to
neighboring cells [12], cytokine exposure and Toll-like receptor
(TLR) stimulation also induces NKG2D ligand transcription [92]. It790 www.drugdiscoverytoday.comis therefore hypothesized that NKG2D ligand expression is tightly
regulated in healthy adult tissue to prevent self-recognition and
autoimmune reactivity. However, in contrast to adult tissue,
NKG2D ligand transcripts are expressed in certain embryonic
tissues, yet are undetectable post-birth [94,95]. This pattern could
coincide with the role of cellular senescence in embryonic devel-
opment, where developmentally programmed senescence occurs
at multiple sites during embryogenesis, contributing to the pat-
terning of mammalian embryos and facilitating tissue remodeling
[96,97].
Although senescent cells can be effectively cleared in young
organisms, it is possible the decreased production of immune cells
during aging (immunosenescence) could reduce an aged orga-
nism’s ability of carrying effective senescence surveillance. A
decline in immune function with age is consistent with the high
numbers of senescent cells observed at old age [13]. Additionally,
the accumulation of senescent cells and their SASP factors could
form a milieu permissive for the retention of senescent cells,
[3_TD$DIFF]similar to the immunosuppresive microenvironment observed
in tumors. Because of this, therapies that boost the immune system
by increasing the number of immune cells, or their activity against
senescent cells, could help older patients in aiding senescence
surveillance.
Although neither a specific nor universal surface marker(s) has
been reported for senescent cells, the selective expression of
NKG2D ligands in many tumor cell lines and primary tumors
has made them emerge as promising targets in oncology. Adop-
tive therapies involving the transfer of immune cells targeting
NKG2D ligands have demonstrated therapeutic potential leading
to long-term improved outcomes in cancer patients [98–101].
Nevertheless, adoptive transfer therapies can lead to life-threat-
ening adverse effects, whereas additional downsides also limit
their use in the clinic, including unfeasible times and costs
dedicated to T cell culture for reaching large enough numbers
of cells, the need to enhance T cell memory and effector char-
acteristics to achieve longer persistence and an adequate selection
of target antigens [102]. Finally, directly targeting the NKG2D
receptor or its ligands is an alternative approach under investiga-
tion. Strategies employing monoclonal antibodies or bispecific
proteins to simultaneously target NKG2D ligands in target
cells and effector immune cells show therapeutic potential in
oncology [92], suggesting their use could be explored for the
development of senotherapeutics.
Selective elimination of senescent cells
Senescent cells make use of various pro-survival mechanisms to
remain viable following DNA damage while simultaneously ham-
pering growth. For instance, much like cancer cells, senescent cells
have an active DDR and rely on antiapoptotic pathways to persist
in tissues. Such mechanisms include the PI3K pathway, involved
in survival regulation [103], the Bcl-2/Bcl-xL pathways which
regulate mitochondrial-dependent apoptosis [104] and the block-
age of dependence receptors that normally promote apoptosis
[105]. These features make senescent cells much more reliant on
pro-survival pathways than their nonsenescent counterparts, serv-
ing as the rationale behind the development of senolytic drugs,
which aim to eliminate senescent cells without affecting quiescent
and proliferating cells [26].
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FIGURE 3
Elimination of senescent cells. Various drugs have been shown specifically to lead senescent cells to apoptosis. Particularly, interference with the phosphoinositide

















WA number of senolytic drugs have now been identified (Fig. 3),
including quercetin (which inhibits the PI3K pathway), dasatinib
(which interferes with dependence receptor EFNB) and ABT263 or
navitoclax (which targets the Bcl-2/Bcl-xL proteins) [26,106].
These drugs report a wide range of beneficial effects for senes-
cence-related indications in vitro and in vivo; most notably en-
hanced cardiovascular function, improved exercise endurance,
reduced osteoporosis and frailty [26,106], as well as radioprotec-
tion and rejuvenation of the hematopoietic system in mice [29].
Although promising, senolytics described to date are not effective
in all senescent cell types, and must instead be tested in each
senescent cell type of interest. Dasatinib effectively eliminated
senescent human fat cell progenitors, yet was much less effective
on senescent human umbilical vein cells (HUVECs). The opposite
phenomenon was observed with quercetin, a natural polyphenol
that works as a potent antioxidant and metal ion chelator [107].
Indeed, quercetin induced cell death of senescent HUVECs to a
greater extent than that of proliferating cells; however, it was
much less effective on targeting pre-adipocytes [26]. In the same
way, themore recently described Bcl-2/Bcl-xL inhibitor navitoclax
was initially suggested as a broad-spectrum senolytic, with lethal
effects in HUVECs, IMR90 human lung fibroblasts and murine
embryonic fibroblasts (MEFs) [106]. However, navitoclax had no
effect on senescent pre-adipocytes, arguably the most abundant
type of senescent cells, in humans [108].Also challenging, despite the apparent cell-type dependency,
the targeted antiapoptotic pathways might not be specific enough
and can be expressed in off-target cell-types, contributing to
unwanted toxicities. For example, transient thrombocytopenia
and neutropenia are well-known side-effects reported upon ad-
ministration of navitoclax [109]. These side-effects could in fact
relate to the importance of Bcl-2 in the survival of lymphocytes
and platelets in a normal setting, such as preventing the activation
of apoptosis that normally follows induction of double-strand
breaks during genetic recombination events [110]. A similar re-
sponse might occur in melanocytes, following the UV-induced
DNA damage they must endure to produce melanin. In fact, Bcl-2
has an indispensable role in the survival of melanocyte stem cells
[110], and benign and malignant melanocytic nevi often over-
express the same antiapoptotic pathway [111,112].
Bcl-2 is expressed in numerous human cancers, and was identi-
fied as a drug target over the past decades. In recent years, more-
selective Bcl-2 inhibitors are under development, for instance
those directed against the specific BH4 domain represent novel
strategies for lowering toxicity [113]. Alternatively, metabolic
differences between senescent and nonsenescent cells could also
be exploited for the development of senolytics. Certainly, similar
to cancer cells, senescent cells display a heightenedmetabolic flux,
which includes enhanced uptake of amino acids, higher protein
quantity and synthesis rates, and strong skewing of transcriptswww.drugdiscoverytoday.com 791















Wtoward genes linked to protein maturation and protein processing
[114,115]. An augmented protein production is explained, at least
partly, by the increased secretory phenotype of senescent cells.
Moreover, enhanced glucose uptake for aerobic glycolysis is a well-
recognized hallmark of cancer cells shared with therapy-induced
and oncogene-induced senescent cells [115]. Importantly, senes-
cent cells not only display a hypermetabolic condition but also
rely on it for survival, as demonstrated by selectively susceptible
death of therapy-induced or oncogene-induced senescent cells
using 2-DG, a false substrate for glycolytic metabolism [115].
In addition to higher energy consumption, increased protein
production also exerts important proteotoxic stress, causing se-
nescent cells to depend on metabolic compensatory mechanisms.
In fact, senescent cells also rely on autophagy and an intact
lysosomal protein degradation machinery to relieve proteotoxic
stress by degrading improperly folded, potentially toxic proteins
[115]. Using specific inhibitors of lysosomal V-ATPases (bafilomy-
cin A1 or concanamycin A), or a cocktail of lysosomal protease
inhibitors, Dorr et al. demonstrated higher metabolic death of
therapy induced senescent cells compared with nonsenescent
cells, and improved survival of chemotherapy-treated mice bear-
ing lymphomas [115]. Put together, these findings highlight the
opportunity of using metabolic targeting for selective elimination
of senescent cells. However, given the oncologic background of
the cells tested, the selective susceptibility of senescent cells
derived from alternative inducers such as replicative or paracrine
senescence remains to be evaluated.
Reactivation of cell proliferation
Aging tissues display a progressive decline in regenerative capaci-
ties leading to age-dependent loss of organ function and impaired
homeostasis. These changes have been attributed to degenerative
changes in tissue-specific stem cells and their niches [116]. Muscle
weakness and frailty correlate with a higher incidence of cells
expressing senescent markers. Impaired stem cell self-renewal has
been linked to replicative senescence, as a direct consequence of
telomere shortening, which activates DDR signaling eventually
leading to pRB/p16INK4a [2_TD$DIFF] activation and SAGA [117]. Additional
studies confirm p16INK4a promotes aging phenotypes in stem cells,
whereas its silencing can enhance the regenerative potential of
brain and bone marrow stem cells [118,119].
The reactivation of cell proliferation in senescent cells would
therefore appear of interest for improving the regenerative capaci-
ty of aged tissues. Although growth arrest in senescent cells is
considered essentially irreversible, genetic and pharmacological
strategies have shown SAGA can be overridden. The upregulation
of telomerase, for instance, reverses telomere attrition and effec-
tively bypasses senescence as shown in vitro [120], whereas the
ectopic expression of chromodomain-containing protein 8
(CBX8), a polycomb group protein that regulates proliferation
through direct binding to the p16INK4a locus, also leads to bypass
of senescence and cellular immortalization [121].
Growth arrest is reinforced in an autocrine manner by the SASP
cytokines IL-6 and IL-8 [12]. IL-8 is recognized by the chemokine
receptor CXCR2 which is upregulated on the surface of senescent
cells and preneoplastic lesions. Thus, using a selective and
competitive inhibitor of CXCR2 (SB225002), Acosta et al. could
bypass oncogene-induced senescence in vitro [10]. Comparably,792 www.drugdiscoverytoday.comneutralizing antibodies against IL-6 or knockdown of IL-6 or its
receptor (IL-6R) also result in bypass of senescence [11]. Of interest,
Kuilman and colleagues additionally showed the transcription
factor C/EBPb was recruited to the promoters of IL-6 and IL-8 in
response to oncogenic stress [11], suggesting C/EBPb might be an
interesting target for overcoming growth arrest.
Retroviral-based functional genetic screens have identified sev-
eral genes regulating bypass of senescence and immortalization
(either by gain or loss of function). These include inactivation of
cell-cycle regulatory genes such as p16INK4a, p21Cip1/Waf1, p53, pRB
or PPP1CA; and overexpression of oncogenic protein/transcrip-
tion factors such as Klf4, c-Myc, Bmi-1 or viral oncogenes [122].
However, most of these genes are widely altered in human tumors
and are most probably implicated in their causality.
More recently, Abad et al. demonstrated in vivo reprogramming
of adult cells was capable of restoring their proliferative potential.
Reprogramming was achieved through the transitory induction of
the four transcription factors Oct4, Sox2, Klf4 and c-Myc in mice,
which led to the generation of induced pluripotent stem cells in
situ, demonstrating reprogramming can be performed within tis-
sues [123]. These findings are relevant for future applications in
regenerative medicine, and partly indicate similar approaches
could restore proliferation in senescent cells or in cells that have
been arrested by non-cell-autonomous effect.
Potential side-effects of interfering with senescent cells
Cell autonomous
Cellular senescence was initially identified as a permanent growth
arrest in cells where multiple replication cycles gradually resulted
in telomere attrition. Replicative senescence was therefore pro-
posed as a cell-autonomous tumor-suppressive mechanism dis-
abling cell division in cells that would otherwise result in aberrant
chromosomal recombination and genomic instability. According-
ly, the same role is defined in oncogene-induced senescence and
therapy-induced senescence, where overcoming growth arrest in
cells with widespread DNA damage or oncogenic activation nor-
mally results in hyperplastic anomalies. In fact, virtually all hu-
man cancers lack functional p53/p21Cip1/Waf1 and/or RB/p16INK4a
pathways, in addition to often carryingmutations in genes known
to collaborate in vitro to bypass the senescence response [122].
Overcoming SAGA of senescent cells should therefore be
approached with caution.
In genetically modifiedmice enabling the drug-inducible repro-
gramming of adult cells in situ, reprogramming appeared capable
of restoring proliferative potential in multiple tissues. However,
the interventions came at an elevated price, resulting in multiple
teratomas within multiple organs [123]. Interestingly, such effects
were not observed in genetically modified mice enabling drug-
inducible suicide of senescent cells [22–24] suggesting elimination
of senescent cells is perhaps preferable to the bypass of senescence.
Non-cell autonomous
Contrary to the cell-autonomous role of the SASP, non-cell-auton-
omous effects via the SASP are much less clear and context
dependent. For instance, cellular senescence has a recognized role
facilitating wound healing. In genetic models allowing continu-
ous drug-induced removal of senescent cells, delayed wound
healing was observed until the drug stimulus was removed, and

















Wpartially rescued upon topical treatment with recombinant plate-
let-derived growth factor (PDGF)-AA [8].
Additionally, senescent cells have an important role in the
limitation of fibrosis. For instance, cellular senescence limits fi-
brosis by halting the proliferation of stellate cells responsible for
the production of extracellular matrix deposited in fibrotic scar,
and contributes to attract immune cells facilitating wound healing
and fibrosis reversion by secreting extracellular-matrix-degrading
enzymes and SASP components [87]. Suppression of key SASP
components could therefore lead to anomalies in immune cell
recruitment during wound healing or even tumor surveillance. For
instance, inhibition of NK cells delays fibrosis resolution [87];
whereas a reduction in neutrophil recruitment is observed upon
treatment with a CXCR2 antagonist (SB225002) in an experimen-
tal colitis model. However, neutrophil influx only appears critical-
ly dependent on CXCR2 in the early phases (8 h), but not in the
later phases (day 7) [124]. Intermittent interventions for eliminat-
ing senescent cells should therefore allow for removal of chronic
persistent cells, without interfering with normal immune cell
recruitment post-treatment.
Although mice lacking key senescence regulators displayed
excessive fibrosis upon liver injury [85], no effects were observed
in drug-inducible models, perhaps because the senescence re-
sponse drove instead to caspase-mediated apoptosis, thus limiting
the proliferation of stellate cells [24]. Intriguingly, in some con-
texts, chronic senescence can contribute to a fibrotic pathology
rather than ameliorate it, as observed in idiopathic pulmonary
fibrosis (IPF), a progressive and fatal lung disease. In IPF fibroblasts
Nox4 mediates senescence and apoptosis. Genetic and pharmaco-
logic targeting of Nox4 led to a reversal of persistent fibrosis in
aged mice models with a stablished fibrosis phenotype [125]. The
direct effects of senolytic interventions in fibrosis thus remain
unclear. In the same way, loss of senescence in developmentally
programmed senescence was partially compensated by apoptosis
but still resulted in detectable developmental abnormalities [96].
As with most pharmaceuticals, senolytic interventions would
therefore be most probably avoided during pregnancy to prevent
miscarriage or fetal malformation.
In oncology, strategies to suppress the SASP could in theory
interfere with SAGA and even impair tumor surveillance, result-
ing in higher cancer susceptibility. Fortunately, however, phar-
macological interventions reducing the SASP do not appear to
fuel tumor progression, and instead show an opposite effect,
prompting their use in cancer therapies. In fact, many described
senolytics were initially identified as anticancer drugs [26], and
clinical trials have been conductedwithmany of them, including
Bcl-2 inhibitors (e.g., dasatinib, navitoclax) [126] and mTOR
inhibitors such as rapamycin (sirolimus) and rapalogs includingRAD001 (everolimus), CCI-779 (temsirolimus) and AP23573
(deferolimus), to evaluate their anticancer efficacy [127]. Even
more so, the combination of mTOR inhibitors with a Bcl-2 antag-
onist with potential senolytic activity (BDA-366) exhibits excep-
tional synergistic effects against lung cancer [128], markedly
questioning deleterious roles for senolytic interventions in tumor
progression.
Concluding remarks and future perspectives:
pharmacological interventions in humans
Although regeneration capacity deteriorates with age in mam-
mals, it remains intact in other species such as salamanders.
Surprisingly, salamanders show a significant induction of cellular
senescence during limb regeneration; however, rapid and effective
mechanisms of senescent cell clearance operate in regenerating
tissues. Accordingly, the number of senescent cells does not in-
crease upon aging, in contrast to mammals [129]. However, very
recently senescent cells have been shown to promote tissue regen-
eration also in mammals, probably through secretion of specific
SASP factors (Serrano Science). Thus, pharmacological or localized
assisted immunological clearance of senescent cells might poten-
tially aid regeneration of dysfunctional aged tissues.
The various beneficial effects resulting from the administration
of drugs to selectively eliminate senescent cells, or suppress the
deleterious aspects of the SASP, encourage their use in the treat-
ment of age-related disabilities and chronic diseases as a group.
Unfortunately, many challenges are still to be overcome for a
successful drug development program, including increased selec-
tivity and reduction of off-target effects. The optimization of
therapeutic dosage in already approved drugs, now repurposed
for aging interventions, appears promising in the reduction of
unwanted side-effects, as demonstrated for rapamycin using lower
intermittent doses [130]. Additionally, the development of appro-
priate animal models capable of demonstrating the beneficial
effects using clinically relative outcomes is imperative [131]. These
models would ideally be capable of distinguishing on-target from
off-target effects to enable a correct assessment of safety and
efficacy at a preclinical level, and ultimately grant their use in
human clinical trials. In the near future, it is most likely that
interventions against cellular senescence will only be prescribed
on a case-by-case basis, for specific age-related dysfunctions, in
patients with a favorable risk:benefit tradeoff; as is already the case
in oncology where many identified senolytics are currently under
investigation. Promisingly, however, human clinical trials are
already underway to evaluate pharmaceutical impacts on longevi-
ty and human aging as a whole, extending our understanding on
the human biology of aging and suggesting antiaging interven-
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